Beyond DCF: Smarter Valuation Approaches for Deep Tech Startups

India's deep tech sector raised around $2.3 billion in 2025 — a 37% jump from the year before. Thousands of startups are now working across semiconductors, robotics, space tech, and advanced materials. Yet most of them are still being valued the same way as any other startup: using DCF, a method built for companies with predictable revenue.

That's a mismatch. Deep tech doesn't behave like a typical SaaS or consumer startup, and DCF, applied without adjustment, quietly gets the valuation wrong.

Why DCF Struggles With Deep Tech

DCF needs a reasonably confident forecast of future cash flows. Deep tech companies rarely have that. A startup building new semiconductors, biotech platforms, or space hardware might have no revenue for years, face long and uncertain R&D cycles, and end up with an outcome that's essentially binary — the technology either works commercially, or it doesn't.

Budget 2026 extended startup status to twenty years specifically because deep tech ventures need far longer than usual to land a first paying customer — often a government body or public sector undertaking. A valuation method built for near-term, predictable cash flow just isn't designed for a company that may still be years away from its first invoice.

Real Options Valuation

This approach treats the companys milestones—such as a successful pilot, a regulatory clearance or a first commercial contract—, as options that the company may decide to exercise once uncertainty decreases instead of predicting fixed cash flows today.

I find that the approach fits technology well because it measures the value of flexibility directly. The company is not locked into a predicted future; the company can pivot, scale or abandon a research path as results become available. The discounted cash flow method has no way to capture this flexibility; the method either ignores it or forces it into an unrealistic overly smooth growth curve.

Risk-Adjusted NPV (rNPV)

Widely used in biotech, rNPV applies well to Indian deep tech ventures with clear technical milestones too. Instead of one revenue forecast, it assigns a probability of success to each development stage, and weights future cash flows by that probability.

For an Indian medtech startup, this might mean weighting the odds of successful clinical validation, regulatory approval, and market adoption separately — instead of assuming one smooth path to revenue. The result reflects real technical risk, rather than hiding it behind an optimistic growth number.

The VC Method, Adjusted for Longer Timelines

The usual VC method, which is to estimate an exit value and then bring it back to present value still works but you have to change it a lot for deep technology. The exit timeline should be extended a lot. The discount rate must show the extra technical, regulatory and procurement risks on top of normal market risk.

This is especially true in India, where the main problem for technology is not money but getting the first big paying customer, often a government agency. A valuation that assumes a software startup path, to income will keep missing the timeline.

Comparable Deals and Milestone-Based Scenarios

When many similar deals are there. And this is happening more often as Indian deep tech funding expands. Recent transaction multiples can set a valuation more reliably than a guess. In addition milestone‑based scenario modeling. Creating valuation outcomes linked to particular technical or regulatory milestones each weighted by its chance. Is clearer, than a single DCF number because it shows the risk assumptions directly instead of hiding them inside a growth rate.

Why the Right Method Matters

Picking the wrong valuation approach doesn't just produce an inaccurate number. It can affect fundraising, ESOP pricing, and tax compliance. A DCF valuation that assumes near-term revenue can set an ESOP strike price that misrepresents real value to employees, or produce a Rule 11UA valuation that won't hold up given the company's actual stage.

Deep tech in India has grown from a niche category into a genuine pillar of the innovation economy, backed by dedicated government funds and a longer startup runway. Valuing these companies well means using methods that price technical risk, flexibility, and long development timelines directly — not a DCF model borrowed from a business that looks nothing like them.